Press Release

Regenerative Medicine Market to Grow with a CAGR of 9.45% through 2028

Rising number of clinical trials for regenerative therapies and rising awareness for stem cell therapeutics is expected to drive the Global Regenerative Medicine Market growth in the forecast period, 2024-2028.

According to TechSci Research report, Regenerative Medicine Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018–2028F, the Global Regenerative Medicine Market stood at USD 14.67 billion in 2022 and is anticipated to grow with a CAGR of 9.45% in the forecast period, 2024-2028. The is experiencing lucrative growth due to the increasing elderly population and the rising prevalence of chronic conditions like diabetes and cancer. Moreover, advancements in medical technologies, particularly in tissue engineering and stem cell therapy, are driving market growth. Additionally, governments worldwide are taking initiatives to promote research and development in regenerative medicines, accompanied by growing investments by industry players, which are expected to positively impact market growth during the forecast period.

The emergence of stem cell technologies has provided a new platform for the tissue engineering and regenerative medicine market. However, there are still unexplored areas in stem cell technologies, such as umbilical cord blood stem cells, which offer lucrative opportunities for the tissue engineering and regeneration industry. Successful organ regeneration and tissue engineering require highly proliferative and differentiated cell types. Cord blood stem cells, derived from both allogenic and autologous sources, possess advantageous characteristics with regard to immune responses. They do not activate an immune response from the body after implantation. Another type of stem cell is adult stem cells (ASC), which are highly undifferentiated cells that can be modified into various cell types. Derived from bone marrow tissues, these stem cells have better replacement properties than normal cells. The third type of cells, Embryonic Stem Cells (ESC), holds immense potential in the industry.

However, ethical challenges arise due to their collection from babies/fetuses, limiting their commercial and research use. Nevertheless, increasing awareness about tissue engineering and stem cell therapies is expected to address these ethical concerns in the future. Furthermore, stem cells obtained from foreign sources, known as xenogenic cells, show great potential in the regenerative medicine industry. However, they face ethical issues from society. Over time, it is anticipated that these ethical challenges will dissipate as xenogenic cells have the potential to be transformed and practically used in tissue engineering and regeneration.

The increasing prevalence of chronic conditions, such as heart conditions, diabetes, and cancer, is projected to drive market growth. For instance, according to data published by the Centers for Disease Control and Prevention, 37.3 million individuals in the U.S. are afflicted with diabetes. Factors contributing to the rising prevalence of this condition include evolving lifestyles, an aging population, and sedentary habits. Stem cell biology offers promising solutions for diabetes treatment, utilizing various types of stem cells, including embryonic, germline, mesenchymal, and induced pluripotent cells. Advancements in molecular medicines have led to the development of gene-based cell therapy, employing targeted delivery of DNA as medicine to address a wide range of disorders. Furthermore, gene therapy demonstrates significant potential in treating both type 1 and type 2 diabetes, as well as cancer, by restoring gene functions.

Presently, gene-based therapies are utilized in the treatment of cancer, cardiovascular diseases, infectious diseases, genetic disorders, monogenic diseases, ophthalmological indications, and central nervous system conditions, thereby fostering market growth. Government initiatives worldwide are anticipated to provide support for market expansion. For instance, the Canadian Government has announced a funding of USD 20 million to advance regenerative medicine, stem cell, and genomics research within the country. The Stem Cell Network will allocate USD 4.3 million in funding to support research initiatives addressing health challenges associated with cancer, type-1 diabetes, muscular dystrophy, blood disorders, multiple sclerosis, cystic fibrosis, and heart disease. Additionally, Genome Canada will provide USD 16 million in funding to support ten research projects aimed at revolutionizing drug discovery and biomedicine by 2035. Despite these developments, the market's growth is hindered by the need for a more skilled workforce to handle the associated equipment. While there has been significant demand for regenerative medicines in recent years, market growth is impeded by a workforce gap caused by a shortage of skilled laborers with the necessary expertise. Moreover, high costs, coupled with a lack of awareness and ethical concerns surrounding embryonic stem cells, act as adverse factors impacting market growth.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Regenerative Medicine Market


The Global Regenerative Medicine Market is segmented into therapy, material, application, end user, regional distribution, and company.

Based on application, the market is categorized into cardiovascular, oncology, musculoskeletal, wound healing, ophthalmology, and others. The oncology segment holds the largest market share in 2022 and is projected to exhibit lucrative growth during the forecast period. The market's growth is primarily driven by the escalating global prevalence of cancer. For instance, as per an article by Macmillan Cancer Support, the number of people with cancer in the U.K. is estimated to be around 3 million, and this number is expected to exceed 3.5 million by 2025. Furthermore, the increasing demand for personalized treatment is anticipated to fuel the market growth of regenerative medicines.

Based on region, North America segment is expected to grow during the forecast period. North America is projected to hold the largest revenue share, driven by the presence of key players and rapid technological advancements, coupled with significant investments in stem cell and oncology research. The United States stands as the dominant market within the North American region. Notably, there is an escalating prevalence of diseases, such as cancer and diabetes, which now have potential cures through various stem cell therapies in the United States. According to the heart disease  & Stroke Statistical Fact Sheet of 2020, it is estimated that at least 40,000 infants in the United States will be affected by congenital heart defects each year. Of this population, approximately 25%, or 2.4 per 1,000 live births, will require treatment within the first year of life.

The increasing burden of chronic diseases offers new opportunities for market players. Leading industry participants are prioritizing research and development activities to introduce innovative stem cell therapies, thereby fostering the growth of regenerative medicines in the market. For example, a December 2021 article titled "NIH researchers identify potential age-related macular degeneration (AMD) drugs with stem-cell-based research tool" highlights the identification of two drug candidates that may slow down dry age-related macular degeneration (AMD), a leading cause of blindness with no existing treatment, through the use of a stem cell-derived model. Consequently, ongoing research on regenerative medicines is anticipated to drive market expansion in the region.

Major companies operating in Global Regenerative Medicine Market are:

  • Stryker Corporation
  • Athersys, Inc.
  • Integra Lifesciences Corporation
  • Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • Organogenesis Inc.
  • CryoLife, Inc.
  • Medtronic plc
  • U.S. Stem Cell, Inc.
  • Zimmer Biomet Holdings, Inc.
  • 3M Company

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global regenerative medicine market is experiencing significant growth, primarily driven by the increasing adoption of stem cell technologies, gene therapies, and tissue engineering. Technological advancements in regenerative medicine have also played a crucial role in this expansion. Government initiatives and clinical trials focusing on stem cell research have further fueled the market's growth. Regenerative medicines possess a unique ability to alter the fundamental mechanisms of diseases. Ongoing regenerative therapy trials offer promising solutions for specific chronic indications with unmet medical needs. Remarkable progress in molecular medicines has led to the development of gene-based therapy, utilizing targeted DNA delivery to combat various disorders. Gene therapy shows great potential in treating cancer and type 1 & 2 diabetes by restoring gene function. Currently, gene-based therapies are employed in the treatment of cancer, oncology, infectious diseases, cardiovascular disorders, monogenic diseases, genetic disorders, ophthalmological indications, and central nervous system diseases. These factors have significantly contributed to the expansion of the regenerative medicine market.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Regenerative Medicine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy (Stem Cell Therapy, Gene Therapy, Tissue Engineering, And Small Molecule & Biologic), By Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, And Pharmaceuticals), By Application (Cardiovascular, Oncology, Musculoskeletal, Wound Healing, Ophthalmology, And Others), By End User (Hospitals, Specialty Centers, Academic & Research Institutes), By Region and Competition”, has evaluated the future growth potential of Global Regenerative Medicine Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Regenerative Medicine Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News